Cancer research UK centre for drug development: Translating 21st-century science into the cancer medicines of tomorrow
Abstract
The Cancer Research UK Centre (CRUK) for Drug Development (CDD) can trace its origins back to the Cancer Research Campaign Phase I/II Committee (created in 1980) and to date has tested over 120 potential cancer medicines in early-phase clinical trials. Five drugs are now registered, providing benefit to thousands of patients with cancer as part of their routine standard of care. In recent years, the CDD has established several different business and operating models that provide it with access to the pipelines of pharmaceutical and biotechnology companies. This has enabled potential new treatments to be taken into clinical development that might have otherwise languished on companies' shelves and has increased the number of drug combinations being explored in early-phase clinical trials.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Bryostatin 1 has recently entered phase II clinical trial against melanoma, non-Hodgkin's lymphoma, renal cancer and colorectal cancer.
“The bryostatin 1 has recently entered phase II clinical trial against melanoma, non-Hodgkin’s lymphoma, renal cancer and colorectal cancer [58,59,60].”
From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [60]
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · see citing works
Cancer heterogeneity: implications for targeted therapeutics
Fisher, R. A., Pusztai, L., & Swanton, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.581 · Cited by 980 · see citing works
Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692 · see citing works
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689 · see citing works
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 582 · see citing works
Banerji, U., O’Donnell, A. E., Scurr, M. R., Pacey, S., Stapleton, S., Asad, Y. J., Simmons, L., Maloney, A., Raynaud, F. I., Campbell, M. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.612 · Cited by 490 · see citing works
Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
Seymour, L. W., Ferry, D. R., Anderson, D., Hesslewood, S., Julyan, P. J., Poyner, R., Doran, J., Young, A., Burtles, S. S., & Kerr, D. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1668 · Cited by 435 · see citing works
Plummer, R., Jones, C., Middleton, M. R., Wilson, R. H., Evans, J., Olsen, A. L., Curtin, N. J., Boddy, A. V., McHugh, P. J., Newell, D. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1223 · Cited by 386 · see citing works
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382 · see citing works
O’Donnell, A. E., Judson, I. R., Dowsett, M., Raynaud, F. I., Dearnaley, D. P., Mason, M., Harland, S. J., Robbins, A., Halbert, G., Nutley, B. P., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601879 · Cited by 381 · see citing works
Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
Rustin, G. J. S., Galbraith, S. M., Anderson, H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.185 · Cited by 307 · see citing works
Seymour (2009) · International Journal of Oncology · doi:10.3892/ijo_00000293 · Cited by 305 · see citing works
Envisioning the future of early anticancer drug development
Yap, T. A., Sandhu, S. K., Workman, P., & Bono, J. S. D. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2870 · Cited by 279 · see citing works
Benson, C., White, J., Bono, J. S. D., O’Donnell, A. E., Raynaud, F. I., Cruickshank, C., McGrath, H., Walton, M., Workman, P., Kaye, S. B., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603509 · Cited by 261 · see citing works
Kummar, S., Chen, H. X., Wright, J., Holbeck, S. L., Millin, M. D., Tomaszewski, J. E., Zweibel, J., Collins, J. M., & Doroshow, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3216 · Cited by 249 · see citing works
Stanway, S. J., Purohit, A., Woo, L. W. L., Sufi, S., Vigushin, D. M., Ward, R. E., Wilson, R. H., Stanczyk, F. Z., Dobbs, N. A., Kulinskaya, E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1996 · Cited by 240 · see citing works
Pacey, S., Wilson, R. H., Walton, M., Eatock, M. M., Hardcastle, A., Zetterlund, A., Arkenau, H., Moreno‐Farre, J., Banerji, U., Roels, B., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1927 · Cited by 190 · see citing works
Philip, P. A., Rea, D., Thavasu, P., Carmichael, J., Stuart, N. S. A., Rockett, H. R. H., Talbot, D., Ganesan, T. S., Pettit, G. R., Balkwill, F. R., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.22.1812 · Cited by 187 · see citing works
Early phase clinical trials to identify optimal dosing and safety
Cook, N., Hansen, A. R., Siu, L. L., & Razak, A. R. A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.025 · Cited by 136 · see citing works
Pacey, S., Gore, M. E., Chao, D., Banerji, U., Larkin, J., Sarker, S., Owen, K., Asad, Y. J., Raynaud, F. I., Walton, M., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9493-4 · Cited by 136 · see citing works
Jameson, M. B., Thompson, P. I., Baguley, B. C., Evans, B. D., Harvey, V. J., Porter, D. J. T., McCrystal, M. R., Small, M., Bellenger, K., Gumbrell, L. A., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600992 · Cited by 136 · see citing works
Ranson, M., Middleton, M., Bridgewater, J., Lee, S., Dawson, M., Jowle, D., Halbert, G., Waller, S., McGrath, H., Gumbrell, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2198 · Cited by 135 · see citing works
Do molecularly targeted agents in oncology have reduced attrition rates?
Walker, I. A. L., & Newell, H. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2758 · Cited by 128 · see citing works
REES, L. H., Tizard, E. J., Morgan, A. J., et al. (2009) · Transplantation · doi:10.1097/tp.0b013e3181b9d918 · Cited by 126 · see citing works
Chipman, S. D., Oldham, F. B., Pezzoni, G., et al. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.4.375 · Cited by 125 · see citing works
Phase I Study of Copper-Binding Agent ATN-224 in Patients with Advanced Solid Tumors
Lowndes, S. A., Adams, A., Timms, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0315 · Cited by 106 · see citing works
Rustin, G. J. S., Bradley, C., Galbraith, S. M., Stratford, M. R. L., Loadman, P. M., Waller, S., Bellenger, K., Gumbrell, L. A., Folkes, L. K., & Halbert, G. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600885 · Cited by 105 · see citing works
Dean, E. J., Jodrell, D. I., Connolly, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5677 · Cited by 94 · see citing works
Novel Approaches for Targeted Cancer Therapy
Guillemard, V., & Saragovi, H. U. (2004) · Current Cancer Drug Targets · doi:10.2174/1568009043332989 · Cited by 80 · see citing works
Mayer, A., Francis, R. J., Sharma, S. K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0769 · Cited by 80 · see citing works
Hochhauser, D., Meyer, T., Spanswick, V. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1315 · Cited by 79 · see citing works
Meyer, T., Gaya, A. M., Dancey, G. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0035 · Cited by 77 · see citing works
Patterson, D. M., Zweifel, M., Middleton, M. R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2414 · Cited by 75 · see citing works
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
Blackhall, F. H., Ranson, M., Radford, J. A., Hancock, B. W., Soukop, M., McGown, A. T., Robbins, A. K., & Halbert, G. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1624 · Cited by 68 · see citing works
Pritchard‐Jones, K., Spendlove, I., Wilton, C., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602500 · Cited by 49 · see citing works
A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
Madhusudan, S., Protheroe, A. S., PROPPER, D. J., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601321 · Cited by 48 · see citing works
Maxwell‐Armstrong, C., Durrant, L. G., Buckley, T. J. D., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1725 · Cited by 46 · see citing works
Steward, W. P., Middleton, M. R., Benghiat, A., Loadman, P. M., Hayward, C., Waller, S., Ford, S., Halbert, G., Patterson, L. H., & Talbot, D. C. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm120 · Cited by 45 · see citing works
Beale, P. J., Judson, I. R., O’Donnell, A. E., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600854 · Cited by 43 · see citing works
Ehmann, F., Amati, M. P., Salmonson, T., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.14 · Cited by 39 · see citing works
Clamp, A. R., Blackhall, F. H., Vasey, P. A., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601285 · Cited by 39 · see citing works
Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma
Ord, J., Streeter, E. H., Jones, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602650 · Cited by 38 · see citing works
Lee, C. P., Payne, G. S., Oregioni, A., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605425 · Cited by 38 · see citing works
Phase I study of oral JM216 given twice daily
Beale, P. J., Raynaud, F. I., Hanwell, J., et al. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050797 · Cited by 37 · see citing works
Horsley, L., Cummings, J., Middleton, M. R., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2320-9 · Cited by 37 · see citing works
Hughes, A. N., Rafi, I., Griffin, M., Calvert, A. H., Newell, D. R., Calvete, J. A., Johnston, A., Clendeninn, N. J., & Boddy, A. V. (1999) · PubMed · doi:10.25405/ncl.34593561 · Cited by 34 · see citing works
Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1
Danson, S. J., Johnson, P., Ward, T. H., Dawson, M. J., Denneny, O., Dickinson, G. L., Aarons, L. J., Watson, A. J., Jowle, D., Cummings, J., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq638 · Cited by 34 · see citing works
Elkord, E., Dangoor, A., Burt, D. J., Southgate, T. D., Daayana, S., Harrop, R., Drijfhout, J. W., Sherlock, D., Hawkins, R. E., & Stern, P. L. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0674-y · Cited by 30 · see citing works
Cummings, J., Zweifel, M., Smith, N., Ross, P., Peters, J., Rustin, G. J. S., Price, P., Middleton, M. R., Ward, T. H., & Dive, C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.165 · Cited by 25 · see citing works
Jodrell, D., Bowman, A., Rye, R., Byrne, B., Boddy, A. V., Rafi, I., Taylor, G. A., Johnston, A. E., & Clendeninn, N. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690146 · Cited by 14 · see citing works
Newell, D. R., Searle, K. M., Westwood, N., & Burtles, S. S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601106 · Cited by 14 · see citing works
Quinone Oxidoreductase-2–Mediated Prodrug Cancer Therapy
Middleton, M. R., Knox, R. J., Cattell, E., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000615 · Cited by 12 · see citing works
Use of Pd Biomarkers to Drive Dose Selection And Early Clinical Decision Making
Robas, N. M. (2012) · Bioanalysis · doi:10.4155/bio.12.224 · Cited by 9 · see citing works
Cancer charity sees success re-prioritizing industry's shelved compounds
Mullard, A. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4315 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Marine Natural Products: A Source of Novel Anticancer Drugs
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555 · see citing works
- Authors
- Ritchie, J. W. A., & Williams, R. J.
- Affiliations
- Cancer Research UK (GB)
- Corresponding author
- Ritchie, James W.A.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 20
- Issue
- 8
- Pages
- 995-1003
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2025520663
- Cited by
- 7
- References
- 55
- Citations by year
- 2024: 1 · 2023: 1 · 2019: 2 · 2017: 2 · 2015: 1
- FWCI
- 0.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Discovery Today (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK
- National Institute for Health and Care Research
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Science, Research, and Medicine
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Biotechnology and Related Fields
- Keywords
- anticancer drug development, drug development pipeline, combination therapy, translational research, anticancer agents
- MeSH terms
- Academies and Institutes, Animals, Antineoplastic Agents, Clinical Trials as Topic, Cooperative Behavior, Diffusion of Innovation, Forecasting, United Kingdom, Humans, Medical Oncology, Interdisciplinary Communication, History, 21st Century, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
